MDGL
Price
$422.12
Change
-$0.87 (-0.21%)
Updated
Sep 26, 01:11 PM (EDT)
Capitalization
9.43B
34 days until earnings call
RNAC
Price
$9.39
Change
-$0.07 (-0.74%)
Updated
Sep 26, 01:25 PM (EDT)
Capitalization
245.98M
Interact to see
Advertisement

MDGL vs RNAC

Header iconMDGL vs RNAC Comparison
Open Charts MDGL vs RNACBanner chart's image
Madrigal Pharmaceuticals
Price$422.12
Change-$0.87 (-0.21%)
Volume$100
Capitalization9.43B
Cartesian Therapeutics
Price$9.39
Change-$0.07 (-0.74%)
Volume$100
Capitalization245.98M
MDGL vs RNAC Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. RNAC commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and RNAC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (MDGL: $422.99 vs. RNAC: $9.46)
Brand notoriety: MDGL and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 47% vs. RNAC: 172%
Market capitalization -- MDGL: $9.43B vs. RNAC: $245.98M
MDGL [@Biotechnology] is valued at $9.43B. RNAC’s [@Biotechnology] market capitalization is $245.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 4 bullish, 4 bearish.
  • RNAC’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -4.03% price change this week, while RNAC (@Biotechnology) price change was -8.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +7.86%, and the average quarterly price growth was +49.72%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.43B) has a higher market cap than RNAC($246M). MDGL YTD gains are higher at: 37.081 vs. RNAC (-47.180). RNAC has higher annual earnings (EBITDA): -118.73M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. RNAC (160M). RNAC has less debt than MDGL: RNAC (13.3M) vs MDGL (124M). MDGL has higher revenues than RNAC: MDGL (516M) vs RNAC (1.03M).
MDGLRNACMDGL / RNAC
Capitalization9.43B246M3,833%
EBITDA-266.74M-118.73M225%
Gain YTD37.081-47.180-79%
P/E RatioN/A1.98-
Revenue516M1.03M50,292%
Total Cash797M160M498%
Total Debt124M13.3M932%
FUNDAMENTALS RATINGS
MDGL vs RNAC: Fundamental Ratings
MDGL
RNAC
OUTLOOK RATING
1..100
703
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
28100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4088
P/E GROWTH RATING
1..100
10039
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (65) in the Pharmaceuticals Other industry is somewhat better than the same rating for RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than RNAC’s over the last 12 months.

MDGL's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than RNAC’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to RNAC’s over the last 12 months.

MDGL's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for RNAC (88) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that RNAC’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLRNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HMDYX36.10N/A
N/A
Hartford MidCap Y
FXAIX231.17N/A
N/A
Fidelity 500 Index
LBWCX22.11N/A
N/A
BrandywineGLOBAL Div US Large Value C
LZIEX19.99N/A
N/A
Lazard International Equity Instl
VALSX35.13-0.17
-0.48%
Value Line Select Growth Fund

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.90%
ALXO - MDGL
56%
Loosely correlated
+15.48%
NAGE - MDGL
45%
Loosely correlated
-1.16%
IPHA - MDGL
44%
Loosely correlated
-1.09%
RNAC - MDGL
43%
Loosely correlated
-6.06%
GHRS - MDGL
43%
Loosely correlated
-3.67%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-6.06%
TAOX - RNAC
91%
Closely correlated
-8.22%
ALLR - RNAC
86%
Closely correlated
-5.52%
NRXP - RNAC
86%
Closely correlated
-2.68%
PALI - RNAC
81%
Closely correlated
+12.95%
OCUL - RNAC
49%
Loosely correlated
-2.55%
More